CALL FOR PAPERS

CERTIFICATE

IMPACT FACTOR 2018

Subject Area

  • Life Sciences / Biology
  • Architecture / Building Management
  • Asian Studies
  • Business & Management
  • Chemistry
  • Computer Science
  • Economics & Finance
  • Engineering / Acoustics
  • Environmental Science
  • Agricultural Sciences
  • Pharmaceutical Sciences
  • General Sciences
  • Materials Science
  • Mathematics
  • Medicine
  • Nanotechnology & Nanoscience
  • Nonlinear Science
  • Chaos & Dynamical Systems
  • Physics
  • Social Sciences & Humanities

Why Us? >>

  • Open Access
  • Peer Reviewed
  • Rapid Publication
  • Life time hosting
  • Free promotion service
  • Free indexing service
  • More citations
  • Search engine friendly

Plagiarism Detection

IJCR is following an instant policy on rejection those received papers with plagiarism rate of more than 20%. So, All of authors and contributors must check their papers before submission to making assurance of following our anti-plagiarism policies.

Olanzapine ondansetron dexamethasone regime versus aprepitant palonosetron dexamethasone regime for the prevention of chemotherapy-induced nausea and vomiting: rcc study

Author: 
Vishnu H Lal, Rajesh Kumar, Beniwal, S., Akanksha solanki, Trupti Kothari, Murali Paramanandan, Kumar, H.S., Neeti Sharma and Jhakar, S.L
Subject Area: 
Health Sciences
Abstract: 

Background: At the outset of olanzapine gaining popularity as a drug for Chemotherapy induced nausea and vomiting(CINV). Study was conducted with the aim to compare to antiemetic regimes Olanzapine, Ondansetron, Dexamethasone (OOD) with Aprepitant, Palonosetron, Dexamethasone (APD) in patients receiving highly emetogenic chemotherapy. Method: A double bind randomized control study was performed to compare the two antiemetic regimes in patients receiving HEC (Cisplatin>70mg/m2 or Doxorubicin>50mg/m2 and Cyclophosphamide>500mg/m2) with complete response (CR) defined as no vomiting and no rescue (till 5 days post chemotherapy) as the primary endpoint. 270 patients initially allotted to the study of which finally 230 were available for evaluation Results: The primary endpoint of CR was 75% for overall period (92% early period and 75% delayed period) for the OOD arm whereas overall was 70% (81% early period and 70% delayed period) for the APD arm where early period is defined as first 24 hours and delayed as day 2 to day 5 .Nausea control as per MD Anderson Symptom Inventory (MDASI) based questionnaire was better in OOD (60%) vs APD (53%) arm. There was no statistically significant difference between the arms (P>0.05).hence OOD was comparable with APD for prevention of CINV Discussion: study points out an significantly cheaper yet effective option in managing CINV which is a major adverse effect of chemotherapy with repercussions in quality of life and adherence to treatment. The cost factor is of greater significance for a developing country like ours.

PDF file: 

IJMCE RECOMMENDATION

ONLINE PAYPAL PAYMENT

CURRENT ISSUE

NEWS

CHIEF EDITOR
Rosane Cavalcante Fragoso, Brasil
ASSOCIATE CHIEF EDITOR

   

Jean-Marc SABATIER
Chief Scientific Officer and Head of a Research Group
France

Advantages of IJCR

  • Rapid Publishing
  • Professional publishing practices
  • Indexing in leading database
  • High level of citation
  • High Qualitiy reader base
  • High level author suport

EDITORIAL BOARD

Luai Farhan Zghair
Iraq
Hasan Ali Abed Al-Zu’bi
Jordanian
Fredrick OJIJA
Tanzanian
Firuza M. Tursunkhodjaeva
Uzbekistan
Faraz Ahmed Farooqi
Saudi Arabia
Eric Randy Reyes Politud
Philippines
Elsadig Gasoom FadelAlla Elbashir
Sudan
Eapen, Asha Sarah
United State
Dr.Arun Kumar A
India
Dr. Zafar Iqbal
Pakistan
Dr. SHAHERA S.PATEL
India
Dr. Ruchika Khanna
India
Dr. Recep TAS
Turkey
Dr. Rasha Ali Eldeeb
Egypt
Dr. Pralhad Kanhaiyalal Rahangdale
India
DR. PATRICK D. CERNA
Philippines
Dr. Nicolas Padilla- Raygoza
Mexico
Dr. Mustafa Y. G. Younis
Libiya
Dr. Muhammad shoaib Ahmedani
Saudi Arabia
DR. MUHAMMAD ISMAIL MOHMAND
United State
DR. MAHESH SHIVAJI CHAVAN
India
DR. M. ARUNA
India
Dr. Lim Gee Nee
Malaysia
Dr. Jatinder Pal Singh Chawla
India
DR. IRAM BOKHARI
Pakistan
Dr. FARHAT NAZ RAHMAN
Pakistan
Dr. Devendra kumar Gupta
India
Dr. ASHWANI KUMAR DUBEY
India
Dr. Ali Seidi
Iran
Dr. Achmad Choerudin
Indonesia
Dr Ashok Kumar Verma
India
Thi Mong Diep NGUYEN
France
Dr. Muhammad Akram
Pakistan
Dr. Imran Azad
Oman
Dr. Meenakshi Malik
India
Aseel Hadi Hamzah
Iraq
Anam Bhatti
Malaysia
Md. Amir Hossain
Bangladesh
Ahmet İPEKÇİ
Turkey
Mirzadi Gohari
Iran